42 U.S.C. § 284s — Tick-borne diseases

Page 694 TITLE 42—THE PUBLIC HEALTH AND WELFARE § 284r 1 See References in Text note below. Editorial Notes CODIFICATION Section was enacted as part of the Comprehensive Addiction and Recovery Act of 2016, and not as part of the Public Health Service Act which comprises this chapter. § 284r. Basic research (1) Developing policies Not later than 2 years after December 13, 2016, the Director of the National Institutes of Health (referred to in this section as the ‘‘Director of the National Institutes of Health’’), taking into consideration the recommendations developed under section 2039,1 shall develop policies for projects of basic research funded by National In- stitutes of Health to assess— (A) relevant biological variables including sex, as appropriate; and (B) how differences between male and female cells, tissues, or animals may be examined and analyzed. (2) Revising policies The Director of the National Institutes of Health may update or revise the policies devel- oped under paragraph (1) as appropriate. (3) Consultation and outreach In developing, updating, or revising the poli- cies under this section, the Director of the Na- tional Institutes of Health shall— (A) consult with— (i) the Office of Research on Women’s Health; (ii) the Office of Laboratory Animal Wel- fare; and (iii) appropriate members of the scientific and academic communities; and (B) conduct outreach to solicit feedback from members of the scientific and academic communities on the influence of sex as a vari- able in basic research, including feedback on when it is appropriate for projects of basic re- search involving cells, tissues, or animals to include both male and female cells, tissues, or animals. (4) Additional requirements The Director of the National Institutes of Health shall— (A) ensure that projects of basic research funded by the National Institutes of Health are conducted in accordance with the policies developed, updated, or revised under this sec- tion, as applicable; and (B) encourage that the results of such re- search, when published or reported, be disaggregated as appropriate with respect to the analysis of any sex differences. (Pub. L. 114–255, div. A, title II, § 2038(g), Dec. 13, 2016, 130 Stat. 1066.) Editorial Notes REFERENCES IN TEXT Section 2039, referred to in par. (1), is section 2039 of Pub. L. 114–255, which is set out as a note under section 282 of this title. CODIFICATION Section was enacted as part of the 21st Century Cures Act, and not as part of the Public Health Service Act which comprises this chapter. § 284s. Tick-borne diseases (a) In general The Secretary of Health and Human Services (referred to in this section as ‘‘the Secretary’’) shall continue to conduct or support epidemio- logical, basic, translational, and clinical re- search related to vector-borne diseases, includ- ing tick-borne diseases. (b) Reports The Secretary shall ensure that each triennial report under section 283 of this title (as amended by section 2032) includes information on actions undertaken by the National Institutes of Health to carry out subsection (a) with respect to tick- borne diseases. (c) Tick-Borne Diseases Working Group (1) Establishment The Secretary shall establish a working group, to be known as the Tick-Borne Disease Working Group (referred to in this section as the ‘‘Working Group’’), comprised of rep- resentatives of appropriate Federal agencies and other non-Federal entities, to provide ex- pertise and to review all efforts within the De- partment of Health and Human Services re- lated to all tick-borne diseases, to help ensure interagency coordination and minimize over- lap, and to examine research priorities. (2) Responsibilities The working group shall— (A) not later than 2 years after December 13, 2016, develop or update a summary of— (i) ongoing tick-borne disease research, including research related to causes, pre- vention, treatment, surveillance, diag- nosis, diagnostics, duration of illness, and intervention for individuals with tick- borne diseases; (ii) advances made pursuant to such re- search; (iii) Federal activities related to tick- borne diseases, including— (I) epidemiological activities related to tick-borne diseases; and (II) basic, clinical, and translational tick-borne disease research related to the pathogenesis, prevention, diagnosis, and treatment of tick-borne diseases; (iv) gaps in tick-borne disease research described in clause (iii)(II); (v) the Working Group’s meetings re- quired under paragraph (4); and (vi) the comments received by the Work- ing Group; (B) make recommendations to the Sec- retary regarding any appropriate changes or improvements to such activities and re- search; and (C) solicit input from States, localities, and nongovernmental entities, including or- ganizations representing patients, health care providers, researchers, and industry re- Page 695 TITLE 42—THE PUBLIC HEALTH AND WELFARE § 285 1 See References in Text note below. garding scientific advances, research ques- tions, surveillance activities, and emerging strains in species of pathogenic organisms. (3) Membership The members of the working group shall rep- resent a diversity of scientific disciplines and views and shall be composed of the following members: (A) Federal members Seven Federal members, consisting of one or more representatives of each of the fol- lowing: (i) The Office of the Assistant Secretary for Health. (ii) The Food and Drug Administration. (iii) The Centers for Disease Control and Prevention. (iv) The National Institutes of Health. (v) Such other agencies and offices of the Department of Health and Human Services as the Secretary determines appropriate. (B) Non–Federal public members Seven non–Federal public members, con- sisting of representatives of the following categories: (i) Physicians and other medical pro- viders with experience in diagnosing and treating tick-borne diseases. (ii) Scientists or researchers with exper- tise. (iii) Patients and their family members. (iv) Nonprofit organizations that advo- cate for patients with respect to tick- borne diseases. (v) Other individuals whose expertise is determined by the Secretary to be bene- ficial to the functioning of the Working Group. (4) Meetings The Working Group shall meet not less than twice each year. (5) Reporting Not later than 2 years after December 13, 2016, and every 2 years thereafter until termi- nation of the Working Group pursuant to para- graph (7), the Working Group shall— (A) submit a report on its activities under paragraph (2)(A) and any recommendations under paragraph (2)(B) to the Secretary, the Committee on Energy and Commerce of the House of Representatives, and the Com- mittee on Health, Education, Labor, and Pensions of the Senate; and (B) make such report publicly available on the Internet website of the Department of Health and Human Services. (6) Applicability of FACA The Working Group shall be treated as an advisory committee subject to the Federal Ad- visory Committee Act (5 U.S.C. App.).1 (7) Sunset The Working Group under this section shall terminate 6 years after December 13, 2016. (Pub. L. 114–255, div. A, title II, § 2062, Dec. 13, 2016, 130 Stat. 1079.) Editorial Notes REFERENCES IN TEXT Section 2032, referred to in subsec. (b), means section 2032 of Pub. L. 114–255. The Federal Advisory Committee Act, referred to in subsec. (c)(6), is Pub. L. 92–463, Oct. 6, 1972, 86 Stat. 770, which was set out in the Appendix to Title 5, Govern- ment Organization and Employees, and was substan- tially repealed and restated in chapter 10 (§ 1001 et seq.) of Title 5 by Pub. L. 117–286, §§ 3(a), 7, Dec. 27, 2022, 136 Stat. 4197, 4361. For disposition of sections of the Act into chapter 10 of Title 5, see Disposition Table pre- ceding section 101 of Title 5. CODIFICATION Section was enacted as part of the 21st Century Cures Act, and not as part of the Public Health Service Act which comprises this chapter. PART C—SPECIFIC PROVISIONS RESPECTING NATIONAL RESEARCH INSTITUTES SUBPART 1—NATIONAL CANCER INSTITUTE § 285. Purpose of Institute The general purpose of the National Cancer In- stitute (hereafter in this subpart referred to as the ‘‘Institute’’) is the conduct and support of research, training, health information dissemi- nation, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the con- tinuing care of cancer patients and the families of cancer patients. (July 1, 1944, ch. 373, title IV, § 410, as added Pub. L. 99–158, § 2, Nov. 20, 1985, 99 Stat. 832; amended Pub. L. 100–607, title I, § 121, Nov. 4, 1988, 102 Stat. 3054.) Editorial Notes AMENDMENTS 1988—Pub. L. 100–607 inserted ‘‘, rehabilitation from cancer,’’ after ‘‘treatment of cancer’’. Executive Documents WHITE HOUSE CANCER MOONSHOT TASK FORCE Memorandum of President of the United States, Jan. 28, 2016, 81 F.R. 5361, provided: Memorandum for the Heads of Executive Depart- ments and Agencies Cancer is a leading cause of death, and cancer inci- dence is expected to increase worldwide in the coming decades. But today, cancer research is on the cusp of major breakthroughs. It is of critical national impor- tance that we accelerate progress towards prevention, treatment, and a cure—to double the rate of progress in the fight against cancer—and put ourselves on a path to achieve in just 5 years research and treatment gains that otherwise might take a decade or more. To that end, I hereby direct the following: SECTION 1. White House Cancer Moonshot Task Force. There is established, within the Office of the Vice President, a White House Cancer Moonshot Task Force (Task Force), which will focus on making the most of Federal investments, targeted incentives, private sec- tor efforts from industry and philanthropy, patient en- gagement initiatives, and other mechanisms to support cancer research and enable progress in treatment and care. The Vice President shall serve as Chair of the Task Force. (a) Membership of the Task Force. In addition to the Vice President, the Task Force shall consist of the